Galanin and Vasopressin Coexist in the Rat Hypothalamo-Neurohypophyseal System

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Using indirect immunofluorescence methods and antisera raised against galanin (GAL) and vasopressin (VP), we have demonstrated both peptides coexisting in the very same cell bodies in the supraoptic and magnocellular paraventricular nuclei and the magnocellular accessory cells of the lateral hypothalamic area. Furthermore, dehydration and salt loading, which is known to cause release and depletion of VP and oxytocin from the neurohypophysis, also caused a marked reduction of GAL-like immunoreactivity in the posterior lobe of the pituitary but had no effect on hypothalamic GAL immunoreactivity. Systemically administered GAL caused a brief small increase in blood pressure with no effect on heart rate. A thousandfold molar concentration of GAL, compared of VP, was required to induce comparable effects on blood pressure. GAL itself had no modulatory effect on VP-induced pressor response. Systemically administered GAL resulted in mild diuresis whereas VP caused complete and sustained inhibition of diuresis. GAL had no effect on VP-induced anti-diuretis effects. The significance of the coexistence and corelease of GAL and VP remains to be elucidated.

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEN

Journal ID (nlm-ta): Neuroendocrinology

Journal ID (doi): 10.1159/issn.0028-3835

Title: Neuroendocrinology

Publisher: S. Karger AG

ISSN (Print): 0028-3835

ISSN (Electronic): 1423-0194

Publication date Subscription-year: 1989

Publication date (Print): 1989

Publication date (Electronic): 02 April 2008

Volume: 49

Issue: 4

Pages: 419-427

Affiliations

^aDepartment of Zoology, Section of Wildlife Research and Parasitology, University of Graz, Austria; ^bLaboratory of Clinical Science, NIMH, Bethesda, Md., USA, and ^cDepartment of Experimental and Clinical Pharmacology, University of Graz, Austria

Article

Publisher ID: 125147 Other ID: Neuroendocrinology 1989;49:419–427

DOI: 10.1159/000125147

PubMed ID: 2469988

SO-VID: c733b234-8cb4-49b5-8085-6585d074d4ec

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 23 September 1987

Date accepted : 03 August 1988

Page count

Pages: 9

Comments

Comment on this article

scite_